Headquarters: Pleasanton, CA
natus.com
Natus Medical misses by $0.06, beats on revs; guides Q1 EPS below two analyst estimate, revs below two analyst estimate; guides FY19 EPS below two analyst estimate, revs below two analyst estimate
- Reports Q4 (Dec) earnings of $0.43 per share, excluding non-recurring items, $0.06 worse than the two analyst estimate of $0.49; revenues rose 7.3% year/year to $141 mln vs the $135.8 mln two analyst estimate.
- Co issues downside guidance for Q1, sees EPS of $0.01-0.08, excluding non-recurring items, vs. $0.28 two analyst estimate; sees Q1 revs of $111-115 mln vs. $129.30 mln two analyst estimate.
- Co issues downside guidance for FY19, sees EPS of $1.12-1.49, excluding non-recurring items, vs. $1.64 two analyst estimate; sees FY19 revs of $490-510 mln vs. $528.15 mln two analyst estimate.
- Co also announced a significant refreshment of its board of directors with the appointment of Alice D. Schroeder, former CEO and Chair of WebTuner Corporation and Thomas J. Sullivan, President and CEO of A&E Medical Corporation to its board of directors effective February 11, 2019. The company will also nominate Ms. Schroeder and Mr. Sullivan for election at Natus' 2019 Annual Meeting of Stockholders.